Hyperpolypharmacy in patients with chronic kidney disease and its impact on clinical outcomes
Abstract Hyperpolypharmacy (≥ 10 daily medications) is frequent in patients with chronic kidney disease (CKD), but its impact remains poorly characterized. This study, based on 3,011 non-dialyzed, non-transplant CKD outpatients from the CKD-REIN cohort (eGFR < 60 mL/min/1.73 m2) aimed to describe dr...
Збережено в:
| Автори: | , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Nature Portfolio
2026-01-01
|
| Серія: | Scientific Reports |
| Предмети: | |
| Онлайн доступ: | https://doi.org/10.1038/s41598-025-25632-x |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|